ANGELIQ 1.0 MG
DROSPIRENONE : 1.0 MG ESTRADIOL : 1.0 MG · DIN 02268825 · BAYER INC
Health Canada status: MARKETED
What is ANGELIQ?
ANGELIQ 1.0 MG contains DROSPIRENONE : 1.0 MG ESTRADIOL : 1.0 MG. It is listed in the Health Canada Drug Product Database under DIN 02268825, held by BAYER INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 20-Oct-2008. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ANGELIQ used for?
ANGELIQ (drospirenone and estradiol-17β) is indicated for: treatment of the climacteric syndrome (vasomotor symptoms) in postmenopausal women. This may include the treatment of the symptoms of vulvar and vaginal dryness associated with menopause. ANGELIQ is recommended for use only in patients with an intact uterus since the regimen includes a progestin whose role is to assist in the prevention of endometrial hyperplasia.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02268825 |
|---|---|
| Brand name | ANGELIQ |
| Generic / active ingredient | DROSPIRENONE : 1.0 MG ESTRADIOL : 1.0 MG |
| Manufacturer | BAYER INC |
| Strength | 1.0 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | G03FA17 DROSPIRENONE AND ESTROGEN |
| AHFS class | 68:32.00 ; 68:16.04 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 20-Oct-2008 |
| Original market date | 2008-10-20 00:00:00 |
How is it stored and handled?
null
How is it supplied?
null
Is DROSPIRENONE AND ESTROGEN in shortage in Canada?
A Canadian shortage report is on file for this molecule: Active — reported by GLENMARK PHARMACEUTICALS CANADA INC., last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
Who else supplies DROSPIRENONE AND ESTROGEN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. DROSPIRENONE AND ESTROGEN appears in 7 registered pack listings across 2 markets, published on 2 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.